Poor
Needs Review
Patient Risk:
Moderate
Summary
The response makes multiple claims (notably fertility/pregnancy menstrual changes and amenorrhea) that are not supported by the provided COSENTYX label excerpts. Only the indications portion aligns with the provided Indications/Usage sections; mechanism of action is not verifiably supported by the excerpts provided.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported by provided label excerpts: Plaque psoriasis indication (1.1), Psoriatic arthritis indication (1.2), Ankylosing spondylitis indication (1.3).
Unsupported Statements
Cosentyx works by blocking the action of interleukin-17A.
Not supported by the provided label excerpts (none of the shown sections include the mechanism of action wording).
Some studies suggest Cosentyx may affect fertility in women.
No provided label excerpt addresses fertility outcomes in women.
One study reported that women taking Cosentyx experienced a significant decrease in menstrual cycle length and frequency.
No provided label excerpt addresses menstrual cycle length/frequency changes.
In a study involving 20 women with psoriasis, 60% experienced amenorrhea while taking Cosentyx.
No provided label excerpt includes amenorrhea prevalence or study details.
Some studies suggest that biologic medications like Cosentyx may affect fertility by altering hormone levels, disrupting the menstrual cycle, or causing premature ovarian failure.
No provided label excerpt addresses hormone levels, premature ovarian failure, or menstrual disruption for Cosentyx.
Women taking Cosentyx who became pregnant experienced a higher rate of pregnancy complications, including preeclampsia and gestational diabetes.
No provided label excerpt includes pregnancy outcomes/complications (e.g., preeclampsia, gestational diabetes).
A study reporting higher rates of pregnancy complications with Cosentyx had a small sample size.
No provided label excerpt includes study sample size details regarding pregnancy complications.
The impact on fertility with Cosentyx is still a topic of ongoing research.
No provided label excerpt discusses fertility being an ongoing research topic.
Contradictions
Important Omissions
No label-grounded pregnancy or fertility counseling language is provided in the response (the only counseling statement is unsourced by the provided excerpts). If the label includes specific guidance for pregnancy/fertility counseling, it is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response introduces fertility and pregnancy-complication claims without support from the provided COSENTYX label excerpts, which could mislead risk interpretation. The indications claim is aligned with the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Multiple safety-related claims (fertility effects, menstrual changes/amenorrhea, pregnancy complication rates) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to what is present in the provided label excerpts or include only label-supported safety statements (e.g., infections/TB, IBD, immunizations, hypersensitivity/contraindications). For fertility/pregnancy, cite exact label text if provided; otherwise omit.